信达生物:非肿瘤领域即将迎来重磅商业化产品

申万宏源研究
13 Mar

信达生物是一家处于商业化阶段的创新药公司,致力于研发、生产和销售肿瘤、心血管及代谢、自身免疫和眼科等疾病领域的创新药。目前,公司已有超过10 款创新药于国内获批上市。此外,公司有三款产品处于NMPA 审评阶段,包括玛仕度肽、替妥尤单抗,以及匹康奇拜单抗。研发管线方面,目前公司已有四款创新药进入关键临床阶段,以及超20 款创新药处于临床开发阶段。多元化产品组合,商业化持续放量。目前,公司已有超过10...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10